Sugar alcohol sorbitol may supercharge chemo and immunotherapy for stomach cancer
NCT ID NCT06826079
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether taking oral sorbitol, a common sugar alcohol, can enhance the effects of standard chemotherapy and an immunotherapy drug (tirellizumab) in people with locally advanced stomach cancer. Eighty participants will receive either sorbitol or a placebo alongside their cancer treatment for three months. The goal is to see if sorbitol increases the number of patients whose tumors shrink significantly before surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sorbitol
What this could lead to
If it works, this could point toward a simple, cheap way to make standard cancer treatments more effective for gastric cancer patients.
What could go wrong
This is an early phase 2/3 trial with only 80 participants. Sorbitol is a sugar alcohol, and high doses may cause digestive side effects like bloating or diarrhea. The benefit is uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 470000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••